laboratori corp america hldg
believ relief around labcorp earn outlook consist
expect prior commentari lab busi see expect pressur new surpris
result beat lower expect addit covanc result strong across revenu book
final labcorp util free cash flow buy back share repay debt new
repurchas plan author take step back believ labcorp busi model well posit consolid share
time given uniqu scale enterpris capabl reiter overweight rate
 labcorp diagnost post revenu declin y/i came forecast hich reduc
meaning compani guidanc reduct organ volum grow th actual look right
consid eather impact calendar impact assum time relat christma compani
call headw ind netw ork chang press releas though ere like headw ind grow th
quarter impli underli trend ere solid estim total rev-per-req
adjust fx covanc food sale line ith forecast notabl pama headw ind rev-per-
req quarter impli underli mix remain posit
 covanc deliv gross organ grow th total grow th ell forecast
compani ttm book-to-bil impli quarterli book-to-bil quarter believ strength
underli grow th book ill reassur oper solid foot amidst healthi fund environ
 capit deploy labcorp deliv share repurchas debt paydow quarter ith
leverag ttm ebitda expect gener free cash flow believ compani flexibl
deploy capit augment grow th compani author new repurchas plan ith earn
 adjust ep result beat forecast remind revis forecast follow ing compani
labcorp issu guidanc view consist compani prior commentari labcorp expect
revenu grow th hich compar model constant currenc grow th expect
estim organ grow th forecast overal covanc constant currenc grow th expect rang total
grow th includ headw ind fx compani guidanc modestli ahead ex-fx forecast
midpoint labcorp diagnost expect show total declin organ chang hen
adjust fx food test sale compar forecast total grow th though model
assum headw ind food sale compani ad expect pama headw ind vs
forecast ere look addit color hat contract may face cut medicaid float rate
ep guidanc repres grow th y/i consist ith forecast remind
industri confer labcorp ceo dave king weigh expect note ould
challeng year labcorp dx rev given price reduct pama ell open
horizon contract hich previous exclus labcorp partial offset headw ind return labcorp in-
netw ork statu ith aetna result factor labcorp dx expect flat dow hich consist ith
forecast declin segment posit ceo king expect strong perform covanc continu hich
consist ith forecast gross organ grow th final model ep grow th consist ith
manag expect modest grow th earn
revenu labcorp report revenu billion forecast driven organ grow th
divest grow th food solut sale fx
look compani two segment
 labcorp diagnost revenu billion includ hat estim organ growth coupl ith net
divest headw ind fx headw ind drive overal declin y/i came forecast
total declin lower meaning follow compani guidanc reduct volum
grow th came estim organ volum also forecast y/i
remind labcorp low ere revenu forecast due combin headw ind
low er hospit referr chang netw ork ith payor advers eather press releas labcorp call
 eather impact calendar impact adjust covanc food sale fx estim revenu per
requisit decreas y/i line forecast keep mind pama headw ind ithin rev-per-req mix
drive chang
 covanc revenu billion ere estim revenu increas y/i ith organ
grow th adjust fx ttm book-to-bil
believ impli quarterli book-to-bil basi view strong close
figur driver labcorp dx perform
cog margin revenu higher expect sg repres net revenu
quarter estim import note due account chang ith cost
revenu optic increas percentag revenu hile sg expens decreas percentag revenu remind
labcorp continu execut upon launchpad initi labcorp compani announc phase launchpad ith
save expect covanc compani anticip save million
addit chiltern cost synergi end ebitda margin came expect due
stronger revenu better sg off-set higher expect cost revenu
adjust ebit adjust ebit ex-amort declin y/i million adj ebit margin percentag net
revenu declin y/i hich estim labcorp diagnost margin declin
y/i hile covanc drug develop margin improv diagnost adjust oper incom
impact pama million er day quarter million eather disposit food solut
ep adjust ep ex-amort increas y/i estim street
ep modest help line item includ low er interest expens low tax rate compani
share count came roughli line ith estim
flow capit deploy flow oper came million estim million
cffo repres adjust net incom quarter adjust million tax payment relat food test
sale model cffo would come estim quarter capital-expenditure million
repres net revenu y/i capit deploy consist million share repurchas
million debt repay million acquisit labcorp repurchas million share deploy
million tow ard result labcorp announc updat share repurchas author enabl billion
labcorp continu gener signific free cash flow believ compani flexibl activ capit
deploy market compani expect gener free cash flow rang million billion
million though note neg impact eurofin tax payment million labcorp
exit net debt ebitda
pleas reach us ith question
meehan cfa herebi certifi view express research report accur reflect person view
subject secur issuer refer research report part compens ill
directli indirectli relat specif recommend view express research report
barclay capit inc and/or one affili seek busi ith compani cover research report
result investor aw firm may conflict interest could affect object report investor
consid report singl factor make invest decis
barclay research produc invest bank barclay bank plc affili collect individu
barclay author contribut research report research analyst unless otherw ise indic public date
top report reflect local time report produc may differ releas date provid gmt
avail disclosur
 compani subject research report current import disclosur regard compani pleas
refer http //publicresearch barclay com altern send ritten request barclay research complianc seventh
avenu floor new york ny call
analyst respons prepar research report receiv compens base upon variou factor includ
firm total revenu portion hich gener invest bank activ profit revenu market
busi potenti interest firm invest client research ith respect asset class cover analyst
analyst regularli conduct site visit view materi oper cover compani barclay polici prohibit
accept payment reimburs cover compani travel expens visit
barclay research depart produc variou type research includ limit fundament analysi equity-link
analysi quantit analysi trade idea recommend contain one type barclay research may differ
contain type barclay research hether result differ time horizon methodolog otherw ise
order access barclay statement regard research dissemin polici procedur pleas refer
http //publicresearch barcap com/s/rd htm order access barclay research conflict manag polici statement pleas
refer http //publicresearch barcap com/s/cm htm
master limit partnership mlp pass-through entiti structur publicli list partnership tax purpos
distribut unit holder may treat return princip investor consult ow tax advisor
invest unit
laboratori corp america hldg lh usd overw eight/neutr cd/ce/d/j/k/l/m/n
valuat methodolog price target repres ep estim
risk may imped achiev barclay research valuat price consider
uncertainti around protect access medicar act pama could impact reimburs clinic lab start
nearer term expect reimburs continu remain pressur least inflationari physician consolid
rate price target histori
laboratori corp america hldg
prior intra-day chang may publish rate secur overw eight
adjust price target
histor stock price price target may adjust stock split dividend
price sourc refinitiv last avail close price relev trade market unless anoth time sourc
indic
